The Centre will carry out research into the development of new ways of treating and monitoring cancer. It draws on an excellent scientific framework in four Yorkshire universities and will work to develop new drugs and biological therapies, and to test them in clinical trials carried out to the highest standards.

We will exploit novel pharmacodynamic (biomarker and/or imaging) as well as pharmacokinetic studies to facilitate the optimal development of new therapies.

• Wide experience of first-in-man and proof-of-principle early clinical trials of small molecules and biotherapies, both as single agents and in combination.
• Designated Early Clinical Trials Group in our newly opened cancer centre at the St James's Institute of Oncology which is co-located with the Leeds Institute of Molecular Medicine on the St James's Campus in Leeds.
• Established reputation in pharmacokinetic/pharmacodynamic studies conducted in GCLP laboratories at the new Institute of Cancer Therapeutics in Bradford.
• Proven ability to develop and produce novel biotherapies in-house then test them in the clinic.
• An international reputation in biomarker research, especially clinical proteomics, and a new GCLP facility for handling and processing clinical samples under construction.
• Expertise in integrating molecular and cellular pathology into clinical trials to identify prognostic and predictive markers.
• Excellence in imaging research at the Centre for Magnetic Resonance Investigations in Hull.